Medicenna Therapeutics Corp. (MDNA:CA) Discusses New Scientific Knowledge From ABILITY-1 Research Evaluating MDNA11 in Most cancers Immunotherapy Transcript

Operator

Welcome to Medicenna Therapeutics KOL Webinar. [Operator Instructions] As a reminder, this convention name is being recorded. When you’ve got any objections, please disconnect right now. I might now like to show the decision over to Dr. Fahar Service provider, President and CEO.

Fahar Service provider
Founder, Chairman, President & CEO

Good morning, good afternoon, everybody, and thanks for becoming a member of us right now. My identify is Dr. Fahar Service provider, President and CEO of Medicenna Therapeutics. We’re thrilled to welcome you to this unique webinar as we focus on thrilling new medical knowledge from our ABILITY-1 research evaluating MDNA11. Earlier than we start, I might prefer to remind everybody that this webinar incorporates forward-looking statements throughout the which means of relevant securities legal guidelines. Ahead-looking statements could also be recognized by means of phrases reminiscent of imagine, could, will, proceed, anticipate, intend, anticipate, ought to, would, may, plan, potential, promise and related expressions. These forward-looking statements are topic to dangers and uncertainties, together with, however not restricted to the dangers inherent in medical drug growth, regulatory approval processes, aggressive elements and different dangers described in Medicenna’s filings with the Securities and Change Fee and Relevant Canadian Securities regulators.

Precise outcomes could differ materially from these expressed or implied by forward-looking statements Medicenna disclaims any obligation to replace these forward-looking statements, besides as required by legislation. For